

ANTARIA LIMITED

ANNUAL GENERAL MEETING SHAREHOLDER PRESENTATION 26 NOVEMBER 2015

Overview

- People
- Product
- Financials
- Strategy
- Outlook
- Formal Business

People - Staff

- General Manager – Warwick Carter
- Total employees –10 FTE
- Sales + Administration – 3
- Product Development – 3
 - Focus on working with distribution partners and brand-owners on end-product formulations – sales support function
 - Introduction of new XP dispersions
 - Development of range of end-formulations
- Production – 4
 - *Alusion*® Facility – 112 Radium Street, Perth
 - *ZinClear*® Facility – 108 Radium Street, Perth
- Manufacturing process not labour intensive and highly scalable
- Direct labour staffing reduced compared to FY14 to reflect lower demand for *Alusion*®

Product - Alusion®

- **Merck KGaA Licencing and Development Agreement**
 - Merck has exclusive right to market and distribute *Alusion*® for certain applications – cosmetics, coatings, printing and plastics
 - Cosmetic application marketed under the Merck *Rona Flair*™ brand principally used for facial make-up
- **Merck Orders Down**
 - *Alusion*® orders only 5 MT for six months to 31 December 2015.
 - In dialogue with Merck regarding lack of orders and apparent failure to pursue applications beyond cosmetics
 - Reviewing all available options to redress the situation
- **Product initiatives beyond Merck**
 - Pursuing applications which do not infringe Merck exclusivity

Product - *ZinClear*[®]

■ Ingredients Business


- Mineral-based UVA and UVB filter with superior transparency and attractive texture/feel when applied to the skin
- XP powder targets larger brand owners
- IM and XP dispersions target mid-size brand owners.
- Europe expected to approve ZnO as authorised UV filter Q1 2016
- XP65COCO - Dispersion
 - First XP dispersion
 - Market take up has been very strong
 - Products using this dispersion are already released
- Developing coated ZnO offering using XP Powder
- Further development of the NanoZ product line

Product - *ZinClear*[®]


■ White Label Business

- Time to market is a substantial impediment to sales and revenue growth – “Shelf-ready” product solution
- Leverage Antaria’s ZnO formulation expertise
- “White label” complements Ingredients business - “try before you buy”
- “All natural” SPF rated product range – highest growth category in the skin care sector across all geographic regions
- Sun creams, daily wear moisturisers, BB cream, sensitive skin, children’s products, lip balms.
- Market specific formulations for Western and Asian consumers
- Product Launch – In Cosmetics Paris 2016


Product - *ZinClear[®]* Distribution Network



Financials



Financials



Strategy

- **Alusion**
 - Address “impasse” order volumes with Merck
 - Promote Alusion for applications outside Merck agreement
- **ZinClear**
 - Expand range of dispersions
 - Grow distribution network
 - Pursue White Label initiative
- **Exploit patents for other product initiatives**
 - Cerium Oxide (Catalysts, Industrial UV filters)
 - Zirconium Oxide (Technical Ceramics)
 - Forming partnerships with leading research institutions
- **Premises**
 - Existing leases expiring and investigating location options

Outlook

■ Sales

- Continued strong performance of the *ZinClear*[®] range will underpin revenues for FY16
- Increased take-up of *ZinClear*[®] is expected in Europe
- White Label business expected to contribute Q4 FY16
- Ongoing uncertainty over *Alusion*[®] revenues

■ Costs

- Operating costs expected to remain unchanged

■ Profit

- Reduction in *Alusion*[®] sales will negatively impact margin
- Increased *ZinClear*[®] sales may not fully compensate for lost *Alusion*[®] margin

Formal Business

- Financial Report
- Remuneration Report
- Election of Directors
 - Ron Higham
 - Lev Mizikovsky
- Other Business

Financial Report

“To table and consider the Company’s annual financial report, the Directors report and the auditor’s report for the year ended 30 June 2015”

Remuneration Report

Resolution 1

To consider and, if thought fit, pass the following as a non-binding ordinary resolution.

“That the section of the report of the Directors for the financial year ending 30 June 2015, dealing with the remuneration of the Directors, secretary and senior executives, be adopted.”

Proxies Received	Voted
For	88,856,030
Against	15,000
Abstain	0

Retirement and Appointment of Director

Resolution 2

To consider and, if thought fit, pass the following ordinary resolution.

“That Mr Ron Higham who retires by rotation in accordance with Rule 6.4(a) of the Company’s constitution and is eligible for re-election, be re-elected as a Director of the Company.”

Proxies Received	Voted
For	88,856,030
Against	15,000
Abstain	0

Retirement and Appointment of Director

Resolution 3

To consider and, if thought fit, pass the following ordinary resolution.

“That Mr Lev Mizikovsky in accordance with Rule 6.2(c) of the Company’s constitution and being eligible and offering himself for election, be elected as a Director of the Company.”

Proxies Received	Voted
For	88,856,030
Against	15,000
Abstain	0

Other Business

Q & A